Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andre Kunert

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Opinion in Immunology|March 27, 2018
Engineering T cells for adoptive therapy: outsmarting the tumorAndre Kunert, Reno Debets
IEEE Transactions on Visualization and Computer Graphics|February 20, 2020
On Motor Performance in Virtual 3D Object ManipulationAlexander Kulik, Andre Kunert, Bernd Froehlich
IEEE Transactions on Visualization and Computer Graphics|May 7, 2019
Multi-Window 3D Interaction for Collaborative Virtual RealityAndre Kunert, Tim Weissker, Bernd Froehlich, et al.
Immunotherapy|June 13, 2015
Adoptive T-cell therapy: a need for standard immune monitoringYarne Klaver, Andre Kunert, Stefan Sleijfer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
T-cell Receptors for Clinical Therapy: <i>In Vitro</i> Assessment of Toxicity RiskAndre Kunert, Matthias Obenaus, Cor H J Lamers, et al.
Frontiers in Immunology|November 23, 2013
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuAndre Kunert, Trudy Straetemans, Coen Govers, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 5, 2016
MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell ResponsesAndre Kunert, Mandy van Brakel, Sabine van Steenbergen-Langeveld, et al.
Journal for Immunotherapy of Cancer|June 10, 2019
CD45RA<sup>+</sup>CCR7<sup>-</sup> CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumabAndre Kunert, Edwin A Basak, Daan P Hurkmans, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Opinion in Immunology|March 27, 2018
Engineering T cells for adoptive therapy: outsmarting the tumorAndre Kunert, Reno Debets
IEEE Transactions on Visualization and Computer Graphics|February 20, 2020
On Motor Performance in Virtual 3D Object ManipulationAlexander Kulik, Andre Kunert, Bernd Froehlich
IEEE Transactions on Visualization and Computer Graphics|May 7, 2019
Multi-Window 3D Interaction for Collaborative Virtual RealityAndre Kunert, Tim Weissker, Bernd Froehlich, et al.
Immunotherapy|June 13, 2015
Adoptive T-cell therapy: a need for standard immune monitoringYarne Klaver, Andre Kunert, Stefan Sleijfer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
T-cell Receptors for Clinical Therapy: <i>In Vitro</i> Assessment of Toxicity RiskAndre Kunert, Matthias Obenaus, Cor H J Lamers, et al.
Frontiers in Immunology|November 23, 2013
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuAndre Kunert, Trudy Straetemans, Coen Govers, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 5, 2016
MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell ResponsesAndre Kunert, Mandy van Brakel, Sabine van Steenbergen-Langeveld, et al.
Journal for Immunotherapy of Cancer|June 10, 2019
CD45RA<sup>+</sup>CCR7<sup>-</sup> CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumabAndre Kunert, Edwin A Basak, Daan P Hurkmans, et al.
Pageof 1